STK33 monoclonal antibody (M06), clone 4F7
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specification
Product Description
Mouse monoclonal antibody raised against a full-length recombinant STK33.
Immunogen
STK33 (AAH31231, 1 a.a. ~ 514 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Sequence
MADSGLDKKSTKCPDCSSASQKDVLCVCSSKTRVPPVLVVEMSQTSSIGSAESLISLERKKEKNINRDITSRKDLPSRTSNVERKASQQQWGRGNFTEGKVPHIRIENGAAIEEIYTFGRILGKGSFGIVIEATDKETETKWAIKKVNKEKAGSSAVKLLEREVNILKSVKHEHIIHLEQVFETPKKMYLVMELCEDGELKEILDRKGHFSENETRWIIQSLASAIAYLHNNDIVHRDLKLENIMVKSSLIDDNNEINLNIKVTDFGLAVKKQSRSEAMLQATCGTPIYMAPEVISAHDYSQQCDIWSIGVVMYMLLRGEPPFLASSEGKLFELIRKGELHFENAVWNSISDCAKSVLKQLMKVDPAHRITAKELLDNQWLTGNKLSSVRPTNVLEMMKEWKNNPESVEENTTEEKNKPSTEEKLKSYQPWGNVPETNYTSDEEEEKQSTTYEKQFPATSKDNFDMCSSSFTSSKLLPAEIKGEMEKTPVTPSQGTATKYPAKSGALSRTKKKL
Host
Mouse
Reactivity
Human
Interspecies Antigen Sequence
Mouse (68)
Isotype
IgG2a Kappa
Quality Control Testing
Antibody Reactive Against Recombinant Protein.
Western Blot detection against Immunogen (82.28 KDa) .
Storage Buffer
In 1x PBS, pH 7.4
Storage Instruction
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
-
Applications
Western Blot (Cell lysate)
STK33 monoclonal antibody (M06), clone 4F7 Western Blot analysis of STK33 expression in Jurkat ( Cat # L017V1 ).Western Blot (Transfected lysate)
Western Blot analysis of STK33 expression in transfected 293T cell line by STK33 monoclonal antibody (M06), clone 4F7.
Lane 1: STK33 transfected lysate(57.9 KDa).
Lane 2: Non-transfected lysate.
Western Blot (Recombinant protein)
Immunoprecipitation
Immunoprecipitation of STK33 transfected lysate using anti-STK33 monoclonal antibody and Protein A Magnetic Bead, and immunoblotted with STK33 MaxPab rabbit polyclonal antibody.Sandwich ELISA (Recombinant protein)
Detection limit for recombinant GST tagged STK33 is 1 ng/ml as a capture antibody.ELISA
-
Gene Info — STK33
-
Interactome
-
Disease
-
Publication Reference
-
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C.
The Journal of Experimental Medicine 2012 Apr; 209(4):697.
Application:WB-Ce, Human, A-549, Calu-1, NCI-H520, MDA-MB-231, MOLM-14 cells.
-
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Dohner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.
Cell 2009 May; 137(5):821.
Application:WB-Ce, WB-Tr, Human, SKM-1 cells.
-
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com